Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 521
Rating:

Prof Walter Fiedler - University of Hamburg, Hamburg, Germany

Prof Walter Fiedler speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a phase II study looking at the use of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.

He explains that the initial dose was reduced as patients suffered diarrhoea and prolonged aplasia but that this reduction resulted in a much more tolerable regime.

Prof Fiedler reports that a response rate of 50% was seen, an impressive result considering that the patient cohort had many negative characteristics.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation